Clinical Trial Update: An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria [Phase 2]

View source ↗

Summary

Phase 2 outpatient trial evaluating ARS-2 for chronic spontaneous urticaria, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• ARS-2

Snippet

Sponsor: ARS Pharmaceuticals, Inc. | Conditions: Urticaria Chronic | Phase 2 | Status: RECRUITING